Biomarkers for Skin Cancer Patients

Dear Colleagues,

Cancer biomarkers can be measured in blood, organ tissue, or bodily fluids, and are increasingly used to identify the presence of malignancy and help to determine its stage, subtype, and whether a patient will respond to treatment, experience recurrent disease, or even die from cancer. Today, biomarkers play a crucial role in the diagnosis, therapy, and management of patients suffering from skin malignancies. Recent advances in detection techniques (e.g., NGS, multicolor flow cytometry, circulating tumor cells) have enabled researchers and physicians to gain greater insights into the molecular mechanisms that underlie pathologies such as skin cancers. Precision treatment regimens, including targeted therapies and immunotherapies, often require the identification of subsets of patients who will respond to the aforementioned regimens. On the other hand, biomarkers are increasingly established to detect patients with more favorable prognosis who may safely waive over-treatment. Moreover, biomarkers may help to identify patients who are at lower risk and may therefore undergo a follow-up regimen that is less strict. However, there are still challenges in the development of novel noninvasive biomarkers with greater clinical performance. The present Special Issue particularly focusses on original research findings and reviews on skin cancer biomarkers, which may include (but are not limited to) genetic, genomic, epigenomic, proteomic, cellular, and morphologic factors predisposing to skin cancers, indicating the presence of skin cancer, or correlating with treatment response and disease outcome. Of course, other types of manuscripts (e.g., case reports, commentaries) are welcome as well.

Prof. Dr. Thilo Gambichler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Dermato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.